Table 4.
Brain morphometric characteristics and lesions.
| Measure (SD) | Non-responder (n = 45) | Responder (n = 43) | p | ||||
|---|---|---|---|---|---|---|---|
| New T2 lesions (# of patients with lesion count) | W24 | W48 | W24 | W48 | |||
| 0 | 36 | 36 | 35 | 33 | < 0.001** | ||
| 1 | 4 | 5 | 3 | 4 | |||
| 2 | 3 | 0 | 1 | 3 | |||
| 3 | 0 | 2 | 0 | 1 | |||
| 5 | 1 | 0 | 0 | 0 | |||
| 6 | 0 | 0 | 1 | 0 | |||
| 7 | 0 | 0 | 0 | 1 | |||
| 8 | 0 | 0 | 2 | 0 | |||
| 9 | 0 | 0 | 1 | 0 | |||
| 11 | 0 | 0 | 0 | 1 | |||
| Unique newly active lesions (# of patients with lesion count) | BL | W24 | W48 | BL | W24 | W48 | |
|---|---|---|---|---|---|---|---|
| 0 | 40 | 33 | 36 | 33 | 34 | 33 | < 0.0005*** |
| 1 | 1 | 6 | 5 | 3 | 2 | 3 | |
| 2 | 3 | 4 | 0 | 2 | 2 | 3 | |
| 3 | 0 | 0 | 1 | 2 | 1 | 1 | |
| 4 | 0 | 0 | 0 | 1 | 0 | 0 | |
| 5 | 0 | 0 | 1 | 0 | 0 | 0 | |
| 6 | 0 | 1 | 0 | 0 | 1 | 1 | |
| 7 | 0 | 0 | 0 | 1 | 0 | 0 | |
| 8 | 0 | 0 | 0 | 0 | 1 | 1 | |
| 11 | 0 | 0 | 0 | 0 | 0 | 1 | |
| 15 | 0 | 0 | 0 | 0 | 1 | 0 | |
| 22 | 0 | 0 | 0 | 0 | 1 | 0 |
| Newly enhancing lesions (# of patients with lesion count) | BL | W24 | W48 | BL | W24 | W48 | |
|---|---|---|---|---|---|---|---|
| 0 | 40 | 36 | 38 | 33 | 36 | 34 | < 0.01* |
| 1 | 1 | 6 | 4 | 3 | 4 | 5 | |
| 2 | 3 | 2 | 1 | 2 | 0 | 0 | |
| 3 | 0 | 0 | 0 | 2 | 1 | 2 | |
| 4 | 0 | 0 | 0 | 1 | 0 | 0 | |
| 5 | 0 | 0 | 0 | 0 | 0 | 2 | |
| 6 | 0 | 0 | 0 | 0 | 1 | 0 | |
| 7 | 0 | 0 | 0 | 1 | 0 | 0 |
| Newly enlarging T2 lesions (# of patients with lesion count) | W24 | W48 | W24 | W48 | |||
|---|---|---|---|---|---|---|---|
| 0 | 42 | 42 | 38 | 38 |
W24: 0.0005*** W48: 0.14 |
||
| 1 | 2 | 0 | 2 | 4 | |||
| 2 | 0 | 1 | 1 | 1 | |||
| 7 | 0 | 0 | 1 | 0 | |||
| 13 | 0 | 0 | 1 | 0 | |||
BL = Baseline; W24 = 24 weeks assessment point; W48 = 48 weeks assessment point; WM = white mater. P values represent comparisons between placebo responders and non-responders for corresponding assessment points. The models include age, sex, age x sex interaction, disease duration and site as terms.